Scarica l'app Stockscreener
47.90
3.87%
-1.93
Dopo l'orario di chiusura:
47.75
-0.15
-0.31%
Precedente Chiudi:
$49.83
Aprire:
$50.13
Volume 24 ore:
519.13K
Relative Volume:
1.07
Capitalizzazione di mercato:
$3.42B
Reddito:
$751.00K
Utile/perdita netta:
$-74.57M
Rapporto P/E:
-43.42
EPS:
-1.1031
Flusso di cassa netto:
$-55.52M
1 W Prestazione:
-7.22%
1M Prestazione:
-9.07%
6M Prestazione:
+108.26%
1 anno Prestazione:
+152.24%
Intervallo 1D:
$47.75
$50.71
Intervallo di 1 settimana:
$47.75
$53.60
Portata 52W:
$12.56
$58.90
Pulse Biosciences Inc Stock (PLSE) Company Profile
Nome
Pulse Biosciences Inc
Settore
Industria
Telefono
510-906-4600
Indirizzo
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, RMD, MDLN, ALC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
47.90 | 3.68B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
391.95 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
176.80 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
218.89 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.61 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.76 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Mizuho | Outperform |
| 2025-07-07 | Iniziato | Oppenheimer | Outperform |
| 2021-07-27 | Iniziato | Stephens | Overweight |
| 2021-03-11 | Iniziato | Maxim Group | Buy |
| 2021-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-12 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation (NASDAQ:PLSE) - Seeking Alpha
Precision Trading with Pulse Biosciences Inc (PLSE) Risk Zones - Stock Traders Daily
Pulse Biosciences stock reports 100 patient trial milestone - AD HOC NEWS
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - benzinga.com
BTIG initiates Pulse Biosciences stock coverage with buy rating By Investing.com - Investing.com Australia
BTIG Initiates Pulse Biosciences at Buy With $70 Price Target - Yahoo Finance
BTIG Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $70 - Moomoo
BTIG initiates coverage of Pulse Biosciences with Buy rating, $70 price target - TradingView
PLSE Initiated by BTIG -- Price Target Set at $70.00 - GuruFocus
Is Pulse Biosciences (PLSE) Fully Valued As Its Thyroid Trial Reaches 100 Patients? - Simply Wall Street
Pulse Biosciences, Inc (PLSE) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings Amidst Volatile Market Conditions - DirectorsTalk Interviews
Pulse Biosciences Launches New ATM Equity Program - theglobeandmail.com
Pulse Biosciences (NASDAQ: PLSE) Launches $85M ATM Offering at $54.21 Per Share - Kalkine Media
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com - Investing.com Australia
Pulse Biosciences Opens New $85 Million At-the-Market Stock Offering - Minichart
Pulse Biosciences enters $85 million equity distribution agreement with Mizuho - Investing.com
Pulse Biosciences completes enrollment in thyroid nodule study By Investing.com - Investing.com Nigeria
Pulse Biosciences Finalizes Enrollment for PRECISE-BTN Trial Evaluating nPulse Vybrance System - Kalkine Media
Pulse Biosciences Completes Enrollment In The PRECISE-BTN Clinical Study Evaluating The nPulse Vybrance Percutaneous Electrode System For Symptomatic Benign Thyroid Nodules - marketscreener.com
Pulse Biosciences (PLSE) Advances PRECISE-BTN Trial as Valuation Reflects High Growth Expectations - GuruFocus
Pulse Biosciences completes enrollment in thyroid nodule study - Investing.com
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules - Business Wire
Why is Pulse Biosciences stock surging today? By Investing.com - Investing.com Nigeria
Pulse Biosciences stock hits all-time high at 56.15 USD By Investing.com - Investing.com Nigeria
Freedom Capital initiates Pulse Biosciences stock with buy rating By Investing.com - Investing.com Australia
Why Pulse Biosciences Stock Popped Today - theglobeandmail.com
Freedom Capital Markets Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $73 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pulse Biosciences stock hits all-time high at 56.15 USD - Investing.com India
$Pulse Biosciences (PLSE.US)$ the squeeze is onnnnnnnn - Moomoo
PLSE Initiates Coverage by Freedom Capital Markets -- Price Targ - GuruFocus
Freedom Capital initiates Pulse Biosciences stock with buy rating - investing.com
PLSE Q2 2026 Earnings: Narrower-Than-Expected Loss Yields 1.96% Surprise But Shares DeclineEPS Miss Report - careplusvn.com
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pulse Biosciences Stock Price Forecast. Should You Buy PLSE? - StockInvest.us
Pulse Biosciences stock holds steady as investors eye recent clinical and financial progress - AD HOC NEWS
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Pulse Biosciences Inc (DE) (PLSE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com - Investing.com Australia
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock - Investing.com India
COO pays nearly $50 a share for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences Inc (DE) (PLSE) Peer Comparison – Compare with Others - Value Research
$Pulse Biosciences (PLSE.US)$ New ATH 🔥 - Moomoo
Pulse Biosciences Reports Teplitsky Liane Rae as New Insider COO - Kalkine Media
Pulse Biosciences stock hits new high as insider buying fuels rally - AD HOC NEWS
Pulse Biosciences stock hits all-time high at 51.0 USD - Investing.com
Pulse Biosciences stock hits all-time high at 51.0 USD By Investing.com - Investing.com Canada
Pulse Biosciences Inc Azioni (PLSE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pulse Biosciences Inc Azioni (PLSE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 31 '26 |
Buy |
48.80 |
1,024 |
49,971 |
3,094 |
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 28 '26 |
Buy |
48.35 |
1,034 |
49,994 |
2,070 |
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 26 '26 |
Buy |
48.23 |
1,036 |
49,971 |
1,036 |
| LAVIOLETTE PAUL A | Chief Executive Officer |
May 11 '26 |
Buy |
19.69 |
15,000 |
295,350 |
15,000 |
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
2.06%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):